In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Payer Power: What Are The Future Implications For Life Science Companies Developing New Products?

Payers cannot control the pricing of new products by biopharmaceutical companies, but their goal is to deliver quality health care in a cost-effective manner. Several payer medical directors representing over 100 million commercially insured members have shared their insights for managing the challenging US market – revealing their thoughts on drug pricing currently, and steps they plan to take in the next 3 to 5 years to better control rising costs.

Market Access Pricing Strategies BioPharmaceutical

Medtech Business Models: All Razor And No Blades – Is “Big Iron” Back In Vogue?

The conventional wisdom in the medtech industry is to pursue the “razor-razor blade” business model, as each placement of capital equipment generates a lucrative annuity of recurring revenues from disposables. The corollary to this conventional wisdom is that so-called “big iron” is to be avoided as, in sharp contrast, it suffers from greater early cash requirements and longer sales cycles that create difficulties forecasting quarterly revenues, and provides no annuities. But that view is no longer the only one that counts, Health Advances CEO Mark Speers argues.

Market Intelligence Business Strategies Commercial

Global Biopharma R&D Productivity And Growth Rankings

Catenion, a biopharma-focused R&D strategy consulting firm, has analyzed the performance of the top-30 biopharma companies in 2018 and outlined major concerns for the future of innovation in drug development. 

Innovation Research and Development Strategies BioPharmaceutical

Conflict Management Strategies: Protect Your Medtech Company Against Three Common Contract Failures

A company’s contracts of today drive its income of tomorrow – but also its disputes. Dorothee Schramm, a partner at Sidley Austin who specializes in international commercial disputes, provides tips on how to avoid partnership conflicts.

Market Intelligence M & A Business Strategies
Advertisement

Datamonitor Healthcare Podcasts


Recent Tweets from In Vivo


Achieving Launch Excellence In The Challenging Healthcare Markets Of Today

Blue Latitude Health and Informa’s Pharma Intelligence have produced a guide to launch excellence for modern healthcare. Download now and discover how you can achieve launch excellence in the challenging healthcare markets of today.

Download Now

Pharma Report Store

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop Now

Growth Explore this Topic

Set Alert for Growth

Latest From Growth

In Vivo's Top M&A Of 2018: Cast Your Vote!

It is time for In Vivo's 11th annual Deals of the Year contest. We've selected 18 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners. (It's free.)

Growth Deals

In Vivo's Top Financing Of 2018: Cast Your Vote!

It is time for In Vivo's 11th annual Deals of the Year contest. We've selected 18 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners. (It's free.)

Deals Growth

In Vivo's Top Alliance Of 2018: Cast Your Vote!

It is time for In Vivo's 11th annual Deals of the Year contest. We've selected 18 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners. (It's free.)

Deals Growth

Innovation Explore this Topic

Set Alert for Innovation

Latest From Innovation

When The Trial Site Is A Living Room: Pharma Explores Virtual Research Options

One day in the future, clinical studies may routinely be carried out in the virtual world, with patients mostly staying put at home instead of traveling to trial sites. For now, sponsors are experimenting with new models for drug development and taking it one step at a time.

Clinical Trials Innovation

Clinical Trials In 2019: Is Biopharma Ready To Tackle The Iron Triangle of Time, Cost and Quality?

The clinical trial embodies the hope and the hassle of biopharma’s mission to develop new drugs for patients. It is an endlessly imperfect process: C-suite calls for more efficiency and speed at lower cost has been the story for decades. But an In Vivo conversation with a leading expert on trial management pinpoints three key trends that suggest better days are ahead for this central pillar of the innovation imperative.

Clinical Trials Innovation

Leadership Explore this Topic

Set Alert for Leadership

Latest From Leadership

Getting A Grip On Costs In Medtech: The Role Of Culture Change And Leadership Support

Consolidation of hospital networks and professionalization of purchasing teams are putting pressure on medtech prices, and they are just two of the factors that are encouraging medtech leaders to renew their focus on spending visibility and accountability. Zero-based budgeting is a tool that could help them deliver a triple win, Patrick O’Hagan and Jason Evers of Bain & Company suggest.

Leadership Financing

Top 10 Most Read Stories Of 2018

Patient access, regenerative medicine and immuno-oncology feature heavily in a list of the Top 10 most read In Vivo features from 2018, highlighting the issues and disease areas that are top of mind for biopharma and medtech leaders.

Leadership BioPharmaceutical

Into 2019: Stakeholders Are Bidding To Re-Engage Medtech's Innovative Engine

"All-hands-on-deck" has been the policy pursued by the US industry association AdvaMed in recent times, as it has sought to play its part in promoting user-friendly, responsive and transparent regulation and market access for medical and digital health care technology. AdvaMed chair Nadim Yared believes that, with one or two noteworthy exceptions, there is more to come in 2019 from a largely improving medtech ecosystem globally.

US States Leadership

Market Access Explore this Topic

Set Alert for Market Access

Latest From Market Access

Into 2019: Regulatory Pressures Of The EU's Medical Device Regulation Will Spread Into Asia

The extra resources, time and expense that the EU Medical Device Regulation (MDR) will mean for companies in Europe has been a dominant theme since spring 2017, but the repercussions on non-European markets that rely on EU medtech legislation – in Asia, for example – are now coming to the fore, says regional medtech regulatory specialist Jack Wong. 

Asia Pacific ASEAN

Into 2019: Risk, Uncertainty And A Return To Product Focus

In view of the political and regulatory threats and opportunities likely to emerge in 2019, for those in the medtech industry, it pays to be vigilant, advises ZS' Brian Chapman. And while some new tech entrants appear to represent a threat to established medtech players, their emergence in general promises significant opportunities for savings and innovation in health care. At the same time, there will likely be a short-term return to both old medtech industry values, and to major M&A.  

Market Access Policy & Regulation

Into 2019: Digital Leads US Policy Innovations, But Public Medtech Scrutiny Grows

Scott Gottlieb's FDA continues to push out policy reforms and experiments at a rapid pace, with special focus on digital and AI technologies. In parallel, US Medicare officials are more publicly signaling plans to roll out policies for a quicker path to reimbursement for new devices. However, public scrutiny of whether device regulations properly protect patient safety is growing, and it could have an impact. 

United States Market Access

Market Intelligence Explore this Topic

Set Alert for Market Intelligence

Latest From Market Intelligence

Deals Shaping The Medical Industry, January 2019

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2018.

Deals Market Intelligence

2018’s Top Biopharma Deal-makers

Even though 2018 did not feature the big influx of biopharma M&A that was expected, there were still encouraging signs that major advancements and breakthroughs in the biotech industry attract buy-outs. Cancer-focused companies and oncology assets again drove volume in alliances and financing transactions.

Deals Market Intelligence

Deals Shaping The Medical Industry, December 2018

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in November 2018.

Deals BioPharmaceutical
UsernamePublicRestriction

Register

Advertisement